Scholarlink

<p>Alterations in extracellular matrix (ECM) architecture and stiffness are hallmarks of aggressive pancreatic cancer progression. However, the mechanisms by which ECM biomechanical properties regulate malignant biological behavior remain unknown. Here, we reveal that calmodulin-dependent protein kinase doublecortin-like kinase 1 (DCLK1) integrates biomechanical signaling and promotes pancreatic cancer cell progression. DCLK1 expression and activation are selectively induced under conditions of high biomechanical stress mediated through the piezo-type mechanosensitive ion channel component 1 (PIEZO1)/calcium/hippocalcin-like protein 1 (HPCAL1) pathway. Consistently, in solid tumor experiments, DCLK1 overexpression under low stiffness conditions facilitates rapid tumor progression and chemoresistance, whereas using calcium inhibitors can partially reverse the adverse effects of DCLK1 overexpression. Conversely, under high stiffness conditions, DCLK1 knockdown inhibits tumor growth and enhances chemosensitivity but attenuates the sensitizing effect of combined calcium inhibitor treatment on chemotherapy efficacy. Mechanistically, DCLK1 interacts with phosphatidylinositol-4-phosphate 5-kinase type 1 alpha (PIP5K1A) by inhibiting its threonine phosphorylation, thereby facilitating PIP5K1A membrane localization. This activates the downstream phosphatidylinositol 3-kinase–protein kinase B (PI3K-AKT) signaling pathway, promoting cancer cell proliferation and chemoresistance. Collectively, these findings establish DCLK1 functions as a context-specific amplifier, exacerbating aggressive tumor progression and chemotherapy resistance in pancreatic cancer. Targeting the calcium/DCLK1 signaling axis may therefore enhance the efficacy of adjuvant therapies in pancreatic cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Matrix stiffness induces Ca2+-DCLK1-PIP5K1A mechanotransduction as a context-specific amplifier in pancreatic cancer progression and chemotherapy resistance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月16日

查看全文
  • Haoxiang Zhang,
  • Chuanbing Zhao,
  • Jiaoshun Chen,
  • Xiaoqing Hu,
  • Jianwei Bai,
  • Long He,
  • Zanglong Deng,
  • Tao Yin

摘要

Alterations in extracellular matrix (ECM) architecture and stiffness are hallmarks of aggressive pancreatic cancer progression. However, the mechanisms by which ECM biomechanical properties regulate malignant biological behavior remain unknown. Here, we reveal that calmodulin-dependent protein kinase doublecortin-like kinase 1 (DCLK1) integrates biomechanical signaling and promotes pancreatic cancer cell progression. DCLK1 expression and activation are selectively induced under conditions of high biomechanical stress mediated through the piezo-type mechanosensitive ion channel component 1 (PIEZO1)/calcium/hippocalcin-like protein 1 (HPCAL1) pathway. Consistently, in solid tumor experiments, DCLK1 overexpression under low stiffness conditions facilitates rapid tumor progression and chemoresistance, whereas using calcium inhibitors can partially reverse the adverse effects of DCLK1 overexpression. Conversely, under high stiffness conditions, DCLK1 knockdown inhibits tumor growth and enhances chemosensitivity but attenuates the sensitizing effect of combined calcium inhibitor treatment on chemotherapy efficacy. Mechanistically, DCLK1 interacts with phosphatidylinositol-4-phosphate 5-kinase type 1 alpha (PIP5K1A) by inhibiting its threonine phosphorylation, thereby facilitating PIP5K1A membrane localization. This activates the downstream phosphatidylinositol 3-kinase–protein kinase B (PI3K-AKT) signaling pathway, promoting cancer cell proliferation and chemoresistance. Collectively, these findings establish DCLK1 functions as a context-specific amplifier, exacerbating aggressive tumor progression and chemotherapy resistance in pancreatic cancer. Targeting the calcium/DCLK1 signaling axis may therefore enhance the efficacy of adjuvant therapies in pancreatic cancer.